Date(s) - 18 Sep 2012
8:15 PM - 10:45 PM
CPD Points: 3 Points
Audience: Open to Anyone
Price: Free to Paid up College Members & Non-Members 25 Euro
- Lumiere – the local Haematology Patient Support Group – Dr David Busuttil
- Multiple Myeloma Current Development – Profs Ralf Angermund
- The Different Faces of Myeloma – Dr David James Camilleri & Dr Alex Gatt
Confirm attendance via sms with your name, surname, registration number and on 79885454 by Friday 14th of September as SPACES ARE LIMITED
Speaker – Prof Ralf Angermund (world reowned authorithy on MM) + case presentations
Multiple Myeloma Current Development
Multiple myeloma (MM) is the second most frequent hematological malignancy, accounting for approximately 1% of all cancers and 10% of all haematological malignancies with an average annual incidence of 3-5/100,000 dependant on the region. Diagnosis of multiple myeloma requires a well defined procedure including blood tests and radiologic imaging. With new imaging techniques and lab techniques as well as cytogentic markers, risk profiles correlating with prognosis can be defined more closely. Some of these are predictive as well requiring special treatment options. Treatment paradigms were stable from the 1960s onwards until about 10 years ago high-dose chemotherapy and further on, novel agents like immunomodulatory agents and proteasome inhibibitor were approved. Prognosis now is very much different from what has been seen in the past.
The presentation will focus on diagnostic procedures, potential early detection as well as current data on treatment of multiple myeloma. New therapeutic options possibly available in the future will be discussed shortly as well. With the novel treatment approaches, a lot of questions now are still or again open to be addressed. Some of these are: When should multiple myeloma be treated? How aggressive should treatment be? What is the goal of therapy? How close can we come to cure multiple myeloma? What is the role of consolidation and maintenance therapy? What to do with patients relapsing from initial therapy? How to deal with myeloma renal disease and myeloma bone disease? What is the current standard of supportive care?
Final answers are not available to date, discussions are ongoing, but key principles have already been defined and could be achieved and assessed with the novel techniques and treatments available to date.
Sponsored by Janssen